Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OMGA

OMGA - Omega Therapeutics, Inc. Stock Price, Fair Value and News

$0.19-0.01 (-5.00%)
Market Closed

77/100

OMGA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

77/100

OMGA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$0.29

Target 3M

$0.22

Target 6M

$0.25

OMGA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OMGA Price Action

Last 7 days

18.8%

Last 30 days

46.2%

Last 90 days

137.5%

Trailing 12 Months

-61.2%

OMGA RSI Chart

OMGA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OMGA Valuation

Market Cap

1.1M

Price/Earnings (Trailing)

-0.02

Price/Sales (Trailing)

0.14

Price/Free Cashflow

-0.02

OMGA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$0.29

Target 3M

$0.22

Target 6M

$0.25

OMGA Fundamentals

OMGA Revenue

OMGA Earnings

OMGA Profitability

Free Cashflow Yield

-5.2K%

OMGA Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.9M6.3M8.1M0
20232.3M2.6M2.8M3.1M
2022626.4K1.1M1.6M2.1M
2021000144.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About Omega Therapeutics, Inc.

OMGA
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers (OEC) for inflammatory lung diseases, such as neutrophilic asthma, acute respiratory distress syndrome, dermatological, oncology, and rheumatological indications; OEC candidates for idiopathic pulmonary fibrosis; liver regeneration medicines; and OEC candidates for patients with diabetes and other conditions to treat corneal epithelial injury. In addition, the company develops OEC candidates for the treatment of alopecia, a disorder characterized by patches of non-scarring hair loss affecting the scalp and body. Omega Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEhttps://omegatherapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES116

Omega Therapeutics, Inc. Frequently Asked Questions

OMGA is the stock ticker symbol of Omega Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Omega Therapeutics, Inc. is 1.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OMGA's fair value in chart for subscribers.

The fair value guage provides a quick view whether OMGA is over valued or under valued. Whether Omega Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Omega Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OMGA.

As of Wed Jan 28 2026, OMGA's PE ratio (Price to Earnings) is -0.02 and Price to Sales (PS) ratio is 0.14. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OMGA PE ratio will change depending on the future growth rate expectations of investors.